This article summarized the latest R&D progress of Pilocarpine Hydrochloride, the mechanism of action for Pilocarpine Hydrochloride, and the drug target R&D trends for Pilocarpine Hydrochloride.

New data from the 2023 ASH conference is now available on the Clinical Results section of the Synapse database.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

The overexpression of BCL-2 protein allows tumor cells to evade apoptosis and to become resistant to a variety of anti-tumor drugs. Bcl-2 inhibitors are a new type of anti-cancer drug developed to target the mechanism of apoptosis, promoting cell death.

This article summarized the latest R&D progress of Perindopril Erbumine, the Mechanism of Action for Perindopril Erbumine, and the drug target R&D trends for Perindopril Erbumine.

At ASH 2023, results of SL-172154 as a single agent and with Azacitidine for relapsed/refractory AML and HR-MDS will be presented, highlighting its safety, pharmacodynamics, and anti-tumor effects.

Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.

ATR, a core DDR kinase, senses replication stress and signals S and G2/M checkpoints to initiate DNA repair. It's a hot target in anti-cancer drug development, with some ATR inhibitors already in clinical trials.

This article summarized the latest R&D progress of Pentostatin, the mechanism of action for Pentostatin, and the drug target R&D trends for Pentostatin.

Recently the clinical trial of Nivolumab, a PD-1 blockade, for the treatment of RR HL was reported at the ASCO Congress.

At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.

Aromatase converts androstenedione to estrogens. In postmenopausal women, it mainly comes from adrenal glands. Aromatase inhibitors target high-risk groups, combined with OFS for endocrine therapy.